The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
A new generation organic platinum analog with an extended spectrum of
antineoplastic activity. Designed to overcome platinum drug resistance,
picoplatin alkylates DNA, forming both inter- and intra-strand
cross-linkages, resulting in inhibition of DNA replication and
transcription, and the induction of apoptosis.